Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Comment by PennyStoc2on Mar 01, 2015 6:40pm
107 Views
Post# 23478044

RE:News release roadmap (expected)

RE:News release roadmap (expected)I don't believe Valeant skin lightening on the shelves on Q2'15. I guess not before Q1'16.
forhandlaren wrote: In terms of upcoming news releases I expect the following - not to mention new compounds not currently known to the public. The timing of NR is of course very difficult to foresee, but nevertheless Sirona should be able to produce these NR in the following months. I expect at least one SP pop to one dollar during the period of time, and a sustainable SP of 50 cents before the years end (2015).

Q1 ‘15
skin lightener TFC-1067 performance (minor SP impact) (announced on/before March 11th)
anti-aging update (minor SP impact) (announced) (announced on/before March 11th)
SGLT2 update (minor SP impact) (announced) (announced on/before March 11th)
 
Q2 ‘15
Valeant skin lightning products on the shelves (major SP impact)
SGLT2 into Phase I (minor SP impact)
 
Q3 ‘15
SGLT2 ROW licensing deal (major SP impact)
anti-inflammatory Bloom Burton into Phase I (minor SP impact)
 
Q4 ‘15
cash-flow Valeant deal (major SP impact)
anti-aging licensing deal (major SP impact)
 
Q1-Q2 ‘16
skin lightening licensing deal non-Valeant (major SP impact)
sunscreen licensing deal (major SP impact) dependency to the anti-aging program
cancer antigen licensing deal (major SP impact)
crop licensing deal Aegilops (minor SP impact)
vaccine preservation licensing deal VitamFero (minor SP impact) dependency to the anti-aging program
anti-infective Bloom Burton into Phase I (minor SP impact)


Bullboard Posts